119,344 Shares in ADMA Biologics, Inc. (NASDAQ:ADMA) Bought by Norges Bank

Norges Bank purchased a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 119,344 shares of the biotechnology company's stock, valued at approximately $2,047,000. Norges Bank owned approximately 0.05% of ADMA Biologics at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. GAMMA Investing LLC lifted its position in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 967 shares during the period. National Bank of Canada FI bought a new position in ADMA Biologics in the 3rd quarter valued at about $35,000. Mark Sheptoff Financial Planning LLC acquired a new position in shares of ADMA Biologics in the 4th quarter valued at approximately $35,000. Vision Financial Markets LLC bought a new stake in shares of ADMA Biologics during the 4th quarter worth approximately $51,000. Finally, AlphaQuest LLC acquired a new stake in shares of ADMA Biologics during the 4th quarter worth approximately $84,000. Institutional investors and hedge funds own 75.68% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

Remove Ads

ADMA Biologics Price Performance

Shares of NASDAQ ADMA traded down $1.27 during mid-day trading on Wednesday, hitting $20.88. 3,106,440 shares of the stock traded hands, compared to its average volume of 3,595,930. The company has a market cap of $4.94 billion, a PE ratio of 74.57 and a beta of 0.53. ADMA Biologics, Inc. has a twelve month low of $5.91 and a twelve month high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The firm has a 50 day simple moving average of $17.96 and a two-hundred day simple moving average of $18.19.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.